Umfang:
Online-Ressource (XXII, 519p. 78 illus., 68 illus. in color, digital)
ISBN:
9781441966940
Serie:
SpringerLink
Inhalt:
This book is written by International experts in their field and should appeal to students and seasoned researchers, to scientists and to clinicians. No prior knowledge of the topic is required to appreciate this text and yet the book charters new territory. New perspectives are given on how our knowledge of cancer development might lead us to reconsider our clinical approach to early detection and prevention of cancer at an individual and population level.
Inhalt:
The majority of cancers present at a relatively advanced stage in which invasion within the primary organ is well established and metastases to lymph and distant organs are either clinically apparent or present at the microscopic level. However, it is increasingly recognized that the natural history of cancer formation is a long and complex path taking many years to develop to a clinically apparent stage in most cases. Furthermore, for most solid tumours there is a pre-invasive or intraepithelial stage of disease. This affords the opportunity for early detection and prevention of invasive disease and hence a cure. However, with this advancing knowledge comes a whole plethora of questions which will be explored in this monograph. Firstly, we need to understand the global burden of pre-invasive disease and what the public health implications might be for wide-scale screening programmes. In the western world we already have experience of screening for cervical, breast, prostate and more recently colon cancer. As well as their potential benefits these programmes have financial and psychosocial implications which need to be carefully weighed. This is especially true since many pre-invasive lesions will not progress to cancer in a individual's lifetime. In addition, there are questions concerning whether screening reduces the cancer burden or in fact distorts the survival figures through lead-time bias. Secondly, at the level of epidemiology and molecular pathogenesis there are important questions regarding the aetiology of pre-invasive lesions, an understanding of which might lead to possible chemopreventive strategies. For example, it would be helpful to know the extent to which the likelihood of developing a pre-invasive lesion is influenced by lifestyle or genetic factors and how these factors influence the risk of progression to invasive disease. At the molecular level we need to understand the pathways and molecular mechanisms, both genetic and epigenetic, by which cells achieve the capacity to invade. Thirdly, in order make clinical progress we need biomarkers to identify and risk stratify individuals with pre-invasive lesions. These biomarkers might be applied to the serum as in Prostate Specific Antigen in prostate cancer or be applied to tissue samples, such as oestrogen receptor status in breast cancer. In order to utilize biomarkers in the context of a screening programme there are issue around the invasiveness of the test as well as its positive and negative predictive value. With advances in molecular imaging there is now the exciting possibility of incorporating a molecular tag to a non-invasive imaging modality. Fourthly, in order to justify screening early detection must be coupled to a treatment strategy. If the chemopreventive agent is very well tolerated, then as well as targeting high risk groups, one might consider treatment at the population level. Aspirin is one such drug which has been extensively assessed in the context of colon cancer chemoprevention trials. Trials of aspirin chemoprevention are now being applied to other cancers such as oesophageal adenocarcinoma and since many individuals take aspirin for .chemoprevention of cardiovascular disease the cancer incidence can be ascertained in these populations. In order to understand the more general issues raised from the discussions above it is useful to consider disease specific examples. Our understanding of pre-invasive disease varies according to the organ site and there are lessons to be learned from these experiences. For example, there is now the prospect of a vaccine for cervical cancer with important questions about how this might be applied to the high incidence areas of the developing world. On the other hand, ductal carcinoma in situ is currently treated by mastectomy which is more radical than the treatment received by many women with invasive disease. Oesophageal adenocarcinoma, which is my own area of expertise is interesting because of the rapid rise in incidence in the western world and the clinically accessible pre-invasive lesion called Barrett's oesophagus. However, most cases of Barrett's oesophagus remain undiagnosed and it is not yet clear how to effectively diagnose, monitor and treat this condition without recourse to mass endoscopy with substantial cost implications.
Anmerkung:
Includes bibliographical references and index
,
Pre-Invasive Disease:Pathogenesis and ClinicalManagement; Preface; Foreword; Questions in the Study of Epithelial Preneoplasia; Summary; References; Contents; Contributors; Part I:Pathogenesis; Chapter 1: Stem Cells in Intraepithelial Neoplasia; Introduction; The Stem Cell Origin of Cancer; Stem Cells in the Development of Intestinal Metaplasiaand Barrett's Oesophagus; Aspects of Molecular Changes in Barrett's Oesophagus; The Nature of Intestinal Metaplasia; The Stem Cell/Clonal Origins of Intestinal Metaplasia; Intestinal Metaplasia is a Clonal Proliferation
,
The Origin of Barrett's MetaplasiaThe Nature of Clonal Competition; Conclusion; References; Chapter 2: The Inflammatory Tissue Microenvironment and the Early Stages of Malignancy; Introduction; Malignant Change Induces Inflammatory Pathways; Tumor-Promoting Inflammation and Pre-invasive Malignancies; Links Between the Intrinsic and Extrinsic Pathwaysof Cancer-Related Inflammation; Cancer-Related Inflammation in Experimental Pre-invasive Lesions; Translating this Knowledge into Clinical Managementof Pre-invasive Malignancy; Conclusion; References
,
Chapter 3: Hereditary Factors and Pre-invasive DiseaseThe Genetics of Cancer; Rare, High Penetrance Cancer Susceptibility Alleles; Common, Low-Penetrance Cancer Susceptibility; The Clinical Utility of Polygenic Disease Risk Prediction; Conclusion; References; Chapter 4: Epigenetic Alterations as Contributors to the Pathogenesis, Detection, Prognosis and Treatment of Human Pre-invasi; Introduction; Dysregulated Epigenetic Mechanisms Occurring in Cancer; ATP-Dependent Chromatin Remodeling; Histone Posttranslational Modifications
,
Polycomb/Trithorax Protein Function and DNA Methylation (Fig. 4.1)Clinical Applications Related to Epigenetic Modifications Occurring in Neoplastic Disease; Biomarkers of Neoplastic and Pre-invasive Disease; Novel Therapeutic Approaches to Neoplastic Disease; Conclusions; References; Chapter 5: The Progression of Pre-invasive to Invasive Cancer; Introduction; The Evolution of Invasive Cancer in the Breast; Normal Epithelium; Hyperplasia; Atypical Hyperplasia; In Situ Carcinoma; Invasive Carcinoma; References
,
Chapter 6: Contribution of the -Omics Era to Our Understanding of Preinvasive Disease and Progression to CancerIntroduction; The -Omic Technologies; Transcriptomics; Expression Analysis; Quantitative Real time polymerase chain reaction (qRT-PCR); miRNA Screen; Genomic DNA Analysis; Array Comparative Genomic Hybridization (aCGH); Single Nucleotide Polymorphism (SNP) Arrays; Proteomics; Application of -Omics Technologies to Selected Preinvasive Diseases; Barrett's Esophagus/Dysplasia/Esophageal Adenocarcinoma; Intestinal Metaplasia/Dysplasia/Gastric Adenocarcinoma
,
Adenoma/Dysplasia/Colorectal Carcinoma
Weitere Ausg.:
ISBN 9781441966933
Weitere Ausg.:
Buchausg. u.d.T. ISBN 978-1-441-96693-3
Sprache:
Englisch
DOI:
10.1007/978-1-4419-6694-0
URL:
Volltext
(lizenzpflichtig)
